← All trials
NCT01229449
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2009
- Primary completion
- Sep 1, 2009
- Completion date
- Sep 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 678
- Arms / groups
- 5 / —
- Source
- AACT · pre-existing
Sponsors
- Reckitt Benckiser PharmaceuticalLead sponsor
- Premier Research GroupOverall official - principal investigator
- Worldwide Clinical TrialsCollaborator
- Aptuit Inc.Collaborator
- Clearcut Clinical ConsultingCollaborator
- ACM Global LaboratoriesCollaborator
- Premier Research GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.